HSE data management reports are prepared monthly and provide detailed performance data for the full suite of Key Performance Indicators [KPIs], and Activity Targets contained in the National Service Plan.

March 2026 - Social inclusion - Opioid Agonist Treatment (p.72)

• SI1 Total no. of clients in receipt of opioid agonist treatment (outside prisons)
• SI64 Mean time in Clinics from referral to assessment for opioid agonist treatment
• SI65 Mean time in Clinics from opioid agonist treatment assessment to treatment commenced

Problem alcohol use(p.72)

• I36 % of problem alcohol users (over 18 years) for whom treatment has commenced within one calendar month following assessment
• SI39 % of problem alcohol users (under 18 years) for whom treatment has commenced within one week following assessment

Needle exchange (p.70)

• I46 No of unique individuals attending the Pharmacy Needle Exchange Programme*

Tobacco (p.7)

• HWB27 No. of smokers who received face to face or telephone intensive cessation support from a HSE trained and accredited stop smoking advisor
• HWB27B No. of smokers who received face to face or telephone intensive cessation support from a HSE trained and accredited stop smoking advisor (Community)
• HWB27C No. of smokers who received face to face or telephone intensive cessation support from a HSE trained and accredited stop smoking advisor (Hospitals)
• HWB27D No. of smokers who received face to face or telephone intensive cessation support from a HSE trained and accredited stop smoking advisor (Quitline)
• HWB101 No. of smokers who are receiving online cessation support services National
• HWB26 % of smokers on cessation programmes who were quit at four weeks National
• HWB110 % of smokers engaging with HSE Stop Smoking Services and using recommended Stop Smoking Medicines

Environmental health (p.14) 

• HWB29 No. of initial tobacco sales and/or nicotine inhaling product sales to minors test purchase inspections carried out 
• WB93 No. of inspections of e-cigarette and refill container manufacturers, importers, distributors and retailers under the E.U. (Manufacture, Presentation and Sale of Tobacco and Related Products) Regulations 2016

*See also, page 200 and 205 for notes on data collection.

[Click here to view performance report for March 2026]

February 2026 - Social inclusion - Opioid Agonist Treatment (p.57)

SI1 Total no. of clients in receipt of opioid agonist treatment (outside prisons)
SI64 Mean time in Clinics from referral to assessment for opioid agonist treatment
SI65 Mean time in Clinics from opioid agonist treatment assessment to treatment commenced

[Click here to view performance report for February 2026]

January 2026 - Social inclusion - Opioid Agonist Treatment (p.68)

SI1 Total no. of clients in receipt of opioid agonist treatment (outside prisons)
SI64 Mean time in Clinics from referral to assessment for opioid agonist treatment
SI65 Mean time in Clinics from opioid agonist treatment assessment to treatment commenced

[Click here to view performance report for January 2026]